Oncotarget

Research Papers:

Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma

Jan-Gowth Chang, Chia-Cheng Chen, Yi-Ying Wu, Ting-Fang Che, Yi-Syuan Huang, Kun-Tu Yeh, Grace S. Shieh _ and Pan-Chyr Yang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:73664-73680. https://doi.org/10.18632/oncotarget.12046

Metrics: PDF 2349 views  |   HTML 2344 views  |   ?  


Abstract

Jan-Gowth Chang1,*, Chia-Cheng Chen2,*, Yi-Ying Wu3,*, Ting-Fang Che4, Yi-Syuan Huang2, Kun-Tu Yeh5,6, Grace S. Shieh2,7,8, Pan-Chyr Yang4,9,10

1Department of Laboratory Medicine and Epigenome Research Center, China Medical University Hospital, China Medical University, Taichung, Taiwan

2Institute of Statistical Science, Academia Sinica, Taipei, Taiwan

3Graduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

4Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

5Department of Pathology, Changhua Christian Hospital, Changhua, Taiwan

6Department of Pathology, School of Medicine, Chung Shan Medical University, Taichung, Taiwan

7Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, Taipei, Taiwan

8Genome and Systems Biology Degree Program, Academia Sinica and National Taiwan University, Taipei, Taiwan

9Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan

10Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

*These authors have contributed equally to this work

Correspondence to:

Grace S. Shieh, email: [email protected]

Keywords: lung adenocarcinoma, TP53, prognosis marker, synthetic lethal, gene expression data

Received: March 18, 2016     Accepted: August 24, 2016     Published: September 15, 2016

ABSTRACT

Two genes are called synthetic lethal (SL) if their simultaneous mutation leads to cell death, but mutation of either individual does not. Targeting SL partners of mutated cancer genes can selectively kill cancer cells, but leave normal cells intact. We present an integrated approach to uncover SL gene pairs as novel therapeutic targets of lung adenocarcinoma (LADC). Of 24 predicted SL pairs, PARP1-TP53 was validated by RNAi knockdown to have synergistic toxicity in H1975 and invasive CL1-5 LADC cells; additionally FEN1-RAD54B, BRCA1-TP53, BRCA2-TP53 and RB1-TP53 were consistent with the literature. While metastasis remains a bottleneck in cancer treatment and inhibitors of PARP1 have been developed, this result may have therapeutic potential for LADC, in which TP53 is commonly mutated. We also demonstrated that silencing PARP1 enhanced the cell death induced by the platinum-based chemotherapy drug carboplatin in lung cancer cells (CL1-5 and H1975). IHC of RAD54B↑, BRCA1↓-RAD54B↑, FEN1(N)↑-RAD54B↑ and PARP1↑-RAD54B↑ were shown to be prognostic markers for 131 Asian LADC patients, and all markers except BRCA1↓-RAD54B↑ were further confirmed by three independent gene expression data sets (a total of 426 patients) including The Cancer Genome Atlas (TCGA) cohort of LADC. Importantly, we identified POLB-TP53 and POLB as predictive markers for the TCGA cohort (230 subjects), independent of age and stage. Thus, POLB and POLB-TP53 may be used to stratify future non-Asian LADC patients for therapeutic strategies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12046